Diffuse cutaneous systemic sclerosis ("dcSSc") is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...
Aisa Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapies for systemic sclerosis, today announced results from its Phase 2 RECONNOITER trial of AISA-021 (cilnidipine), a novel ...
The prevalence of SSc among Alaska Native and American Indian adults is comparable to or higher than other populations, with high GI and pulmonary involvement.
Initial $50M Series A investment from founding investor RTW InvestmentsProceeds will fund clinical development of PRO-203 in systemic sclerosis ...
Nutritional issues such as ARFID are highly prevalent among patients with SSc and can lead to poor outcomes and other systemic complications.
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...
Cabaletta Bio (NASDAQ:CABA) used a fireside chat at TD Cowen’s 46th Annual Health Care Conference to highlight progress ...
Systemic sclerosis is a complex autoimmune condition marked by aberrant immune activation, widespread fibrosis and vasculopathy that affect the skin and multiple internal organs. The disease manifests ...
A retrospective cohort study found that beta-blocker use is associated with a decreased risk for incident HF in certain SAID populations.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Proximal weakness and elevated creatine kinase were ...
A nationwide Swedish register-based study revealed that individuals with systemic sclerosis had a higher risk for hematologic malignancies. Myeloid malignancies typically presented around disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results